Stryker's stock is in a clear downtrend over the past year, with a 1-year price change of -16.46% and a 52-week range of $281.00 to $404.87. The current price of $329.78 sits at approximately 28% of the 52-week range (calculated as (329.78-281.00)/(404.87-281.00) = 0.28), near the lows, suggesting the stock is in a bearish phase and potentially offering a value opportunity if fundamentals support a turnaround. The stock has underperformed the S&P 500 significantly, with a relative strength of -37.09% over the past year, indicating persistent selling pressure relative to the broad market.

Short-term momentum shows a conflicting picture: the 1-month price change is +6.78%, while the 3-month change is -2.76%. This divergence suggests a potential short-term bounce within a longer-term downtrend, possibly driven by oversold conditions or positive news. The 1-month relative strength of +2.71% versus the S&P 500 indicates the stock is starting to stabilize, but the 3-month relative strength of -13.87% confirms the broader weakness. The recent price action from the May low of $282.58 to the current $329.78 shows a recovery of about 16.7%, but the stock remains well below its 52-week high.

Key support is at the 52-week low of $281.00, a break below which could signal further downside toward the $270 area. Resistance is at the 52-week high of $404.87, and a breakout above that level would indicate a reversal of the downtrend. The stock's beta of 0.778 implies it is less volatile than the market, meaning it tends to move less than the S&P 500, which could provide some downside protection in a market sell-off but also limits upside participation in rallies. The current price is 18.5% below the 52-week high, and a move above $350 would be a positive sign of momentum building.

Stryker's revenue trajectory remains solidly growing, with the most recent quarterly revenue (Q4 2025) of $7.171 billion, up 11.42% year-over-year from $6.436 billion in Q4 2024. The multi-quarter trend shows accelerating growth: Q1 2025 revenue was $5.866 billion (+11.9% YoY), Q2 2025 was $6.022 billion (+11.1% YoY), Q3 2025 was $6.057 billion (+10.2% YoY), and Q4 2025 accelerated to +11.4% YoY. Revenue segments show Orthopaedics at $4.964 billion and MedSurg at $4.562 billion, indicating balanced contributions. The consistent double-digit growth supports the investment case for a company with strong demand for its medical devices.

Profitability is robust, with net income of $849 million in Q4 2025 and a net margin of 11.84%, up from 8.48% in Q4 2024. Gross margin improved to 65.22% from 61.98% a year ago, reflecting better cost management or product mix. Operating margin was 27.35% in Q4 2025, compared to 25.84% in Q4 2024, showing margin expansion. The company is clearly profitable with a trailing PE of 41.4x, but the forward PE of 19.7x suggests earnings growth is expected to accelerate significantly.

Stryker's balance sheet is healthy, with a debt-to-equity ratio of 0.73 and a current ratio of 1.89, indicating adequate liquidity. Free cash flow (FCF) for Q4 2025 was $1.875 billion, and trailing twelve-month FCF is $4.283 billion, providing ample cash for acquisitions and dividends. Return on equity (ROE) is 14.48%, and return on assets (ROA) is 7.72%, demonstrating efficient capital use. The company generated $2.143 billion in operating cash flow in Q4 2025, easily covering capital expenditures of $268 million, and has $4.011 billion in cash at period end, giving it financial flexibility.